Ectopic Pregnancy and Miscarriage: Diagnosis and Initial Management in Early Pregnancy of Ectopic Pregnancy and Miscarriage

Total Page:16

File Type:pdf, Size:1020Kb

Ectopic Pregnancy and Miscarriage: Diagnosis and Initial Management in Early Pregnancy of Ectopic Pregnancy and Miscarriage Ectopic pregnancy and miscarriage: Diagnosis and initial management in early pregnancy of ectopic pregnancy and miscarriage National Collaborating Centre for Women’s and Children’s Health Ectopic pregnancy and miscarriage: Diagnosis and initial management in early pregnancy of ectopic pregnancy and miscarriage National Collaborating Centre for Women’s and Children’s Health Commissioned by the National Institute for Health and Clinical Excellence December 2012 Published by the RCOG at the Royal College of Obstetricians and Gynaecologists, 27 Sussex Place, Regent’s Park, London NW1 4RG www.rcog.org.uk Registered charity no. 213280 First published 2012 © 2012 National Collaborating Centre for Women’s and Children’s Health No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK [www.cla.co.uk]. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page. The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use. While every effort has been made to ensure the accuracy of the information contained within this publication, the publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check current indications and accuracy by consulting other pharmaceutical literature and following the guidelines laid down by the manufacturers of specific products and the relevant authorities in the country in which they are practising. This guideline has been fully funded by NICE. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient. Implementation of this guidance is the responsibility of local commissioners and/or providers. ii Contents Contents iii 1 Guideline summary 1 1.1 Guideline development group membership, NCC-WCH staff and acknowledgements 1 1.2 Care pathway 2 1.3 Key priorities for implementation 10 1.4 Recommendations 12 1.5 Key research recommendations 22 1.6 Research recommendations 25 1.7 Schedule for updating the guideline 26 2 Introduction 27 2.1 Early pregnancy complications 27 2.2 For whom is this guideline intended 28 2.3 Related NICE guidance 28 3 Guideline development methodology 29 3.1 Introduction 29 3.2 Developing review questions and protocols and identifying evidence 29 3.3 Reviewing and synthesising evidence 30 3.4 Emotional support 31 3.5 Incorporating health economics 31 3.6 Evidence to recommendations 32 3.7 Stakeholder involvement 33 4 Emotional support and information giving 34 4.1 Introduction 34 4.2 Psychological and emotional support 34 5 Early pregnancy assessment units 47 5.1 Introduction 47 5.2 Clinical and cost effectiveness of early pregnancy assessment units 47 5.3 Model for service organisation and delivery of EPAUs 51 6 Diagnosis of ectopic pregnancy and miscarriage 68 6.1 Signs and symptoms of ectopic pregnancy 68 6.2 Ultrasound for determining a viable intrauterine pregnancy 77 6.3 Accuracy of imaging techniques for diagnosis of an ectopic pregnancy 82 6.4 Diagnostic accuracy of two or more human chorionic gonadotrophin (hCG) measurements for ectopic pregnancy 88 6.5 Diagnostic accuracy of two or more hCG measurements plus progesterone for ectopic pregnancy 93 6.6 Diagnostic accuracy of two or more hCG measurements for viable intrauterine pregnancy 95 6.7 Diagnostic accuracy of two or more hCG measurements plus progesterone for viable intrauterine pregnancy 98 7 Management of threatened miscarriage and miscarriage 103 7.1 Introduction 103 7.2 Progesterone for threatened miscarriage 103 7.3 Expectant management compared with active treatment of miscarriage 111 7.4 Surgical management compared with medical management of miscarriage 122 7.5 Misoprostol and mifepristone for managing miscarriage 135 7.6 Setting for surgical management of miscarriage 176 iii Ectopic pregnancy and miscarriage 8 Management of ectopic pregnancy 182 8.1 Introduction 182 8.2 Surgical compared with medical management of ectopic pregnancy 182 8.3 Laparotomy compared with laparoscopy for ectopic pregnancy 194 8.4 Salpingectomy compared with salpingotomy for ectopic pregnancy 204 9 Anti-D rhesus prophylaxis 213 9.1 Introduction 213 9.2 Anti-D rhesus prophylaxis for threatened miscarriage, miscarriage and ectopic pregnancy 213 9.3 Anti-D rhesus prophylaxis – dose 217 10 Health economics 222 10.1 Introduction 222 10.2 Progesterone for threatened miscarriage 222 10.3 Management of miscarriage 231 10.4 Management of ectopic pregnancy 236 11 References 264 12 Abbreviations and glossary 278 12.1 Abbreviations 278 12.2 Glossary 280 iv 1 Guideline summary 1.1 Guideline development group membership, NCC- WCH staff and acknowledgements GDG members Mary Ann Lumsden Professor of Gynaecology and Medical Education (Chair) Fiona Blake Consultant psychiatrist Nicola Davies General practitioner Karen Easton Consultant nurse Roy Farquharson Consultant obstetrician and gynaecologist Joanne Fletcher Consultant nurse Liz Jones Lay member (stood down July 2011) Julie Orford Lay member (joined July 2011) Caroline Overton Consultant obstetrician and gynaecologist Shammi Ramlakhan Consultant in emergency medicine Helen Wilkinson Lay member National Collaborating Centre for Women’s and Children’s Health (NCC-WCH) Lauren Bardisa-Ezcurra Research fellow (until April 2011) Zosia Beckles Information scientist Liz Bickerdike Research assistant (from April 2012) Rupert Franklin Project manager Maryam Gholitabar Research associate Paul Jacklin Senior health economist David James Clinical co-director (women’s health) Emma Newbatt Research associate Roz Ullman Senior research fellow and clinical lead (midwifery) External advisers Janette Keit Consultant sonographer David Roberts Professor of haematology Acknowledgements Additional support was received from: Wahab Bello, Julie Hodge Allen, Juliet Kenny, Edmund Peston and Wendy Riches at the NCC-WCH 1 Ectopic pregnancy and miscarriage 1.2 Care pathway A. Providing women with information and emotional support Treat all women with early pregnancy complications with dignity and respect. Be aware that women will react to complications or the loss of a pregnancy in different ways. Provide all women with information and support in a sensitive manner, taking into account their individual circumstances and emotional response. (For further guidance about providing information, see Patient experience in adult NHS services [NICE clinical guidance 138, 2012]). Healthcare professionals providing care for women with early pregnancy complications in any setting should be aware that early pregnancy complications can cause significant distress for some women and their partners. Healthcare professionals providing care for these women should be given training in how to communicate sensitively and breaking bad news. Non-clinical staff such as receptionists working in settings where early pregnancy care is provided should also be given training on how to communicate sensi tively with women who experience early pregnancy complications. Throughout a woman’s care, give her and (with agreement) her partner specific, evidence-based information in a variety of formats. This should include (as appropriate): • When and how to seek help if existing symptoms worsen or new symptoms develop, including a 24-hour contact telephone number. • What to expect during the time she is waiting for an ultrasound scan. • What to expect during the course of her care (including expectant management), such as the potential length and extent of pain and/or bleeding, and possible side effects. This information should be tailored to the care she receives. • Information about the likely impact of her treatment on future fertility. • Information about post-operative care (for women undergoing surgery). • What to expect during the recovery period – for example, when it is possible to resume sexual activity and/or try to conceive again, and what to do if she becomes pregnant again. This information should be tailored to the care she receives. • Where to access support and counselling services, including leaflets, web addresses and helpline numbers for support organisations. Ensure that sufficient time is available to discuss these issues with women during the course of their care and arrange an additional appointment if more time is needed. After an early pregnancy loss, offer the woman the option of a follow-up appointment with a healthcare professional of her choice. Throughout the care pathway, where these symbols appear, refer back to section A and provide women with information about: ! Where to seek help in an Where to access support The recovery period emergency and counselling services 2 Guideline summary B. Initial clinical assessment Refer women who are Women with pain and/or bleeding, or haemodynamically unstable, or in atypical symptoms suggestive of whom there is significant concern early pregnancy problems [see about the degree of pain or recommendation 11]
Recommended publications
  • “Why Do They Want to Make Me Suffer Again?” the Impact of Abortion Prosecutions in Ecuador
    HUMAN “Why Do They Want to RIGHTS WATCH Make Me Suffer Again?” The Impact of Abortion Prosecutions in Ecuador “Why Do They Want to Make Me Suffer Again?” The Impact of Abortion Prosecutions in Ecuador Copyright © 2021 Human Rights Watch All rights reserved. Printed in the United States of America ISBN: 978-1-62313-919-3 Cover design by Rafael Jimenez Human Rights Watch defends the rights of people worldwide. We scrupulously investigate abuses, expose the facts widely, and pressure those with power to respect rights and secure justice. Human Rights Watch is an independent, international organization that works as part of a vibrant movement to uphold human dignity and advance the cause of human rights for all. Human Rights Watch is an international organization with staff in more than 40 countries, and offices in Amsterdam, Beirut, Berlin, Brussels, Chicago, Geneva, Goma, Johannesburg, London, Los Angeles, Moscow, Nairobi, New York, Paris, San Francisco, Sydney, Tokyo, Toronto, Tunis, Washington DC, and Zurich. For more information, please visit our website: http://www.hrw.org JULY 2021 ISBN: 978-1-62313-919-3 “Why Do They Want to Make Me Suffer Again?” The Impact of Abortion Prosecutions in Ecuador Summary ........................................................................................................................... 1 Key Recommendations ....................................................................................................... 8 To the Presidency ...................................................................................................................
    [Show full text]
  • Clinical Updates in Reproductive Health
    JULY 2013 © Richard Lord © Richard Clinical Updates in Reproductive Health Please use and share widely: www.ipas.org/clinicalupdates Also available in Spanish: www.ipas.org/actualizacionesclinicas For more information, email [email protected] Clinical Updates in Reproductive Health July 2013 Clinical Updates in Reproductive Health are designed to provide Ipas staff, trainers, partners and other health-care providers with access to up-to-date, evidence-based recommendations. In general, the recommendations are the same as those in the World Health Organization's 2012 Safe Abortion: Technical and Policy Guidance for Health Systems, Second edition. In rare cases, the recommendations have been modified due to the settings where we work. In addition, if there is more current evidence to inform the recommendations, they will be updated here. Ipas works around the world to increase women's ability to exercise their sexual and reproductive rights, especially the right to safe abortion. You can find more information at www.ipas.org. Revisions: This document is updated twice a year; please see the “last reviewed” date for each topic. The information for each Clinical Update topic is current through the listed “last reviewed” date, meaning all relevant published literature up to that date has been considered and included where appropriate. Clinical Updates in Reproductive Health Acknowledgements Editor: Alice Mark Thanks to the following people for giving their time and expertise to the development of this publication: Dalia Brahmi Laura Castleman Jennifer Colletti Alison Edelman Mary Fjerstad Rodolfo Gomez Ponce de Leon Alice Mark Bill Powell Jessica Reinholz Lisette Silva Thanks also to Ipas staff and consultants who contributed to the development of previous versions of the content in this publication: Rebecca Allen Lynn Borgatta Anne Burke Catherine Casino Talemoh Dah Gillian Dean Bela Ganatra Vinita Goyal Bliss Kaneshiro Radha Lewis Patricia Lohr Lisa Memmel Regina Renner 2 Clinical Updates in Reproductive Health CURH-E13July 2013 © 2013 Ipas.
    [Show full text]
  • ICMA 3Rd International Conference
    ICMA April 2010 NEWS newsletter n.2 Asia Safe Abortion Partnership Latin American Consortium Eastern European Alliance African Network Against Unsafe Abortion For Reproductive Choice for Medical Abortion SHARING NEWS! ICMA 3rd international conference On March 2, 2010 over 170 clinicians, • Mifepristone has been approved in ad- public health officials and advocates from 60 ditional countries countries around the world came together for the Third International Conference on Medical • Information about medical abortion is more Abortion sponsored by the International available to women across borders Consortium on Medical Abortion (ICMA) in collaboration with IPAS and Gynuity. • Nepal, Ethiopia, Columbia, Mexico City, Switzerland, Portugal and Spain have either The conference “Expanding access to medical legalized abortion or expanded the grounds abortion: Building on two decades of experi- on which an abortion is considered legal Ended with a lively session on “next ence” steps” in which the four ICMA-affiliated • Low-cost mifepristone and misoprostol regional networks shared their action Reviewed the current status of medical products, including combined products, have plans, ICMA pledged to convene a fourth abortion internationally and highlighted become more available international conference to move the key issues in advancing access to medical global agenda forward while continuing abortion, including strategies for mak- • Several new provision models, including so- to support regional work, and the floor ing medical abortion more accessible, cial marketing of misoprostol and education suggested innovative ideas and strate- overcoming political opposition, and of pharmacists, have been piloted gies such as convening regional network the debate over how much supervision meetings of physicians and midwives, women need when using medications to • Safe internet provision of medical abortion partnering with the International end a pregnancy.
    [Show full text]
  • Abortion, an Increasing Public Health Concern in Ecuador, a 10-Year Population-Based Analysis
    Journal name: Pragmatic and Observational Research Article Designation: ORIGINAL RESEARCH Year: 2017 Volume: 8 Pragmatic and Observational Research Dovepress Running head verso: Ortiz-Prado et al Running head recto: Overall mortality and morbidity rates due to abortion in Ecuador open access to scientific and medical research DOI: http://dx.doi.org/10.2147/POR.S129464 Open Access Full Text Article ORIGINAL RESEARCH Abortion, an increasing public health concern in Ecuador, a 10-year population-based analysis Esteban Ortiz-Prado1–4, Objectives: To describe the epidemiology of abortion in Ecuador from 2004 to 2014 and Katherine Simbaña5,6, Lenin compare the prevalence between the public and the private health care systems. Gómez5,6, Anna M Stewart- Methods: This is a cross-sectional analysis of the overall mortality and morbidity rate due to Ibarra4,7, Lisa Scott8, abortion in Ecuador, based on public health records and other government databases. Gabriel Cevallos-Sierra9 Results: From 2004 to 2014, a total of 431,614 spontaneous abortions, miscarriage and other 1OneHealth Research Group, Faculty of types of abortions were registered in Ecuador. The average annual rate of abortion was 115 Medicine, Universidad De Las Americas, Quito, per 1,000 live births. The maternal mortality rate was found to be 43 per 100,000 live births. Ecuador; 2Department of Cellular Biology, Physiology and Immunology, Institute of Conclusions: Abortion is a significant and wide-ranging problem in Ecuador. The study sup- Biomedicine, Universitat de Barcelona, Spain; 3Department of Physiology, Faculty of Medicine ports the perception that in spite of legal restrictions to abortion in Ecuador, women are still For personal use only.
    [Show full text]
  • King's Research Portal
    King’s Research Portal DOI: 10.1002/14651858.CD007223.pub4 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Kim, C., Barnard, S., Neilson, J. P., Hickey, M., Vazquez, J. C., & Dou, L. (2017). Medical treatments for incomplete miscarriage. Cochrane Database of Systematic Reviews, 2017(1), [CD007223]. https://doi.org/10.1002/14651858.CD007223.pub4 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • Medical Treatments for Incomplete Miscarriage (Review)
    Cochrane Database of Systematic Reviews Medical treatments for incomplete miscarriage (Review) Kim C, Barnard S, Neilson JP, Hickey M, Vazquez JC, Dou L Kim C, Barnard S, Neilson JP, Hickey M, Vazquez JC, Dou L. Medical treatments for incomplete miscarriage. Cochrane Database of Systematic Reviews 2017, Issue 1. Art. No.: CD007223. DOI: 10.1002/14651858.CD007223.pub4. www.cochranelibrary.com Medical treatments for incomplete miscarriage (Review) Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 6 OBJECTIVES ..................................... 7 METHODS ...................................... 7 RESULTS....................................... 11 Figure1. ..................................... 13 Figure2. ..................................... 17 Figure3. ..................................... 18 Figure4. ..................................... 19 Figure5. ..................................... 20 Figure6. ..................................... 21 ADDITIONALSUMMARYOFFINDINGS . 36 DISCUSSION ..................................... 40 AUTHORS’CONCLUSIONS . 41 ACKNOWLEDGEMENTS . 42 REFERENCES ..................................... 42 CHARACTERISTICSOFSTUDIES . 55 DATAANDANALYSES. 101 Analysis 1.1. Comparison 1 Misoprostol versus expectant care, Outcome 1 Complete miscarriage. 111
    [Show full text]
  • Download Here
    Table of Contents PART I – Regional Trends ............................................................................................. 4 Africa - Dipika Nath and Carrie Shelver ............................................................................ 5 Comments by Sylvia Tamale ........................................................................................... 5 Questions and suggestions raised in the discussion ....................................................... 6 The Middle East - Paul Amar ............................................................................................ 8 Comments by Akshay Khanna ......................................................................................... 9 Questions and suggestions raised in the discussion ..................................................... 10 China – Huang Yingyang ................................................................................................ 11 Comments by Cai Yipying .............................................................................................. 11 Questions and suggestions raised in the discussion ..................................................... 12 India – Vivek Divan ........................................................................................................ 13 Comments by Malu Marin ............................................................................................ 13 Questions and suggestions raised in the discussion ..................................................... 14 Latin America -
    [Show full text]
  • Lee FAV SB664 Uploaded By: Senator Lee, Senator Lee Position: FAV
    Lee_FAV_SB664 Uploaded by: Senator Lee, Senator Lee Position: FAV March 11, 2020 Senate Judicial Proceedings Committee SB 664 – Declaration of Rights – Right to Privacy Senate Bill 664 proposes an amendment to the Maryland constitution that enshrines Marylanders right to privacy and freedom from government intrusion as Article 48 of the Declaration of Rights. The language broadly provides that each individual has a natural, essential, and inherent right to privacy that guarantees freedom from government intrusion. The proposed amendment specifically enumerates Marylanders right to live free from government and non-government intrusion caused by the unauthorized collection of personal data. An individual’s right to privacy has been recognized as a fundamental human, social and political right by the international community. Article 12 of the Universal Declaration of Human Rights enumerates a right to privacy, as does the International Covenant on Civil and Political Rights, to which the U.S. is a signatory and a party. Further, 11 state Constitutions have an explicit provision regarding the right to privacy. Six of these states explicitly enumerate privacy as an individual right separate from protections against unreasonable searches and seizures. Those six states run the gambit of ideological diversity from California to Montana to Florida to Alaska. The deep purple state of New Hampshire added an individual right to privacy to their Constitution in 2018 with bipartisan backing in the both legislative chambers and over 80% support from voters on a subsequent referendum. The broad right to individual privacy is accepted as the norm across the world and in many states around the country; it should be an explicit right of all Marylanders.
    [Show full text]
  • The Abortion Game: Writing a Consciously Political Narrative Nonfiction Work
    The Abortion Game: Writing a Consciously Political Narrative Nonfiction Work A PhD research thesis (Creative Writing), with manuscript (creative component) and exegesis (analytical component), submitted for the College of Arts, Victoria University Jacinda Woodhead June 2015 Woodhead | PhD manuscript and exegesis i The Abortion Game: Writing a Consciously Political Narrative Nonfiction Work Abstract In this creative‐writing research project, I set out to create a narrative nonfiction manuscript that investigates the contemporary politics surrounding abortion. The fundamental question driving the creative manuscript was, ‘Why is abortion largely invisible in Australia?’ Abortion is the second‐most common therapeutic surgical procedure in Australia, yet the history, the politics and the practice of abortion remain hidden from view. This invisibility allows us to avoid grappling with and confronting the complicated issues abortion raises. Using techniques commonly associated with fiction writing, such as narrative arc, characterisation, dialogue and scenes, the 69,000‐word manuscript investigates the factors, tiers and characters involved with abortion in Australia. The narrative nonfiction manuscript should be read first. The manuscript is accompanied by a 31,500‐word exegesis analysing the production, lineage and ethical implications of consciously political narrative nonfiction, a term that refers to works that make deliberate political interventions. Similarly to Hartsock (2000), I argue that when writing a consciously political narrative nonfiction work, the writer does not objectify the world as something different or alien from the reader, and instead strives to render characters as complex human beings. The exegesis reviews theories of ethics, objectivity and narrative within a form that is fundamentally journalism, yet can never fit within this narrow definition as it is primarily about mapping the cultural other (Sanderson 2004).
    [Show full text]
  • Abortion Worldwide 2017: Uneven Progress and Unequal Access
    Uneven Progress and Unequal Access Uneven Progress and Unequal Access Susheela Singh Lisa Remez Gilda Sedgh Lorraine Kwok Tsuyoshi Onda Acknowledgments his report was written by Susheela Singh, Lisa San Francisco, and Fundación Oriéntame and TRemez, Gilda Sedgh, Lorraine Kwok and Tsuyoshi Fundación Educación para la Salud Reproductiva Onda—all of the Guttmacher Institute. It was (USA and Colombia); Ilana Dzuba, Gynuity (USA); edited by Jared Rosenberg; Michael Moran and Katy Footman, Marie Stopes International (UK); Kathleen Randall were responsible for production. Diana Greene Foster, University of California, San Francisco; Beth Fredrick, Johns Hopkins Bloomberg The authors thank the following Guttmacher School of Public Health (USA); Chimaroake colleagues for their comments and help in Izugbara, African Population and Health Research developing this report: Akinrinola Bankole, Sneha Centre (Kenya); Shireen Jejeebhoy, Independent Barot, Onikepe Owolabi, Ann Starrs and Gustavo Researcher (India); Katherine Mayall, Center for Suarez, for reviewing a draft of the report; Jonathan Reproductive Rights (USA); Ndola Prata, University Bearak, for invaluable assistance with data; Suzette of California, Berkeley; Mahesh Puri, Center for Audam and Mia Zolna, for data analysis; Alanna Research on Environment, Health and Population Galati, Rachel Jones, Elizabeth Nash and Anna Activities (Nepal); Mónica Roa, Independent Popinchalk, for providing follow-up data; and Alex Consultant (Colombia); Zeba Sathar, Population Arpaia for research support. They
    [Show full text]
  • Dissenting Fiction Re-Righting Law: Practice-Led Research Into Biopolitics, Women’S Rights and Reproductive Justice in Ecuador
    Dissenting fiction re-righting law: practice-led research into biopolitics, women’s rights and reproductive justice in Ecuador María Teresa Galarza Neira ORCID ID 0000-0003-3358-9125 Submitted in partial fulfilment of the requirements of the degree of Doctor of Philosophy (by creative work and dissertation) Victorian College of the Arts Faculty of VCA and MCM The University of Melbourne October-2017 1 Abstract Through a feature-length screenplay and accompanying dissertation this creative practice as research project addresses questions of biopolitics, women’s rights and reproductive justice. The research focuses on my own country, Ecuador, but alludes to a broader Latin American context. In this research, the practice of fiction screenplay writing configured my own understanding of the addressed issues. Based on this understanding, in the dissertation, reflecting upon “The Ladies Room” screenplay, I formulate an explanation around these issues. The first chapter of the dissertation focuses on the legislative context of “The Ladies Room” story. The second, third, fourth and fifth chapters articulate the possible world the screenplay proposes, relative to our four protagonists, respectively. The first chapter juxtaposes Ecuadorian Constitutional and Criminal Law, and public policy, against international human rights instruments with regard to women’s rights. Through the screenplay’s character of Isabel, the second chapter interrogates reproductive coercion and access to safe abortion, the notion of potentiality (not) to, the institution of motherhood and the practice of mothering. The third chapter revolves around Marcia, and how this female character embodies forms of biopolitical power that discipline the body and regulate the population; this chapter also reflects upon the family as an institution and the differential valuation between productive and reproductive work.
    [Show full text]
  • Uso Del Misoprostol En Obstetricia Y Ginecología- FLASOG- 2013
    USO DE MISOPROSTOL EN OBSTETRICIA Y GINECOLOGÍA - 2013 Impresión con la contribución de: Tecnoquímicas, Totalmente Confiable Uso del Misoprostol en obstetricia y ginecología Tercera edición Mayo 2013 1 MANUAL FLASOG Impresión con la contribución de: Tecnoquímicas, Totalmente Confiable 2 USO DE MISOPROSTOL EN OBSTETRICIA Y GINECOLOGÍA - 2013 Impresión con la contribución de: Tecnoquímicas, Totalmente Confiable USO DE MISOPROSTOL EN OBSTETRICIA Y GINECOLOGÍA Tercera Edición Mayo 2013 3 USO DE MISOPROSTOL EN OBSTETRICIA Y GINECOLOGÍA - 2013 EDITORES Hoover O. Canaval Erazo Edgar Iván Ortiz Lizcano Comité Ejecutivo de FLASOG José Fernando De Gracia (Presidente) Sara Edith Campana (Vicepresidente) Flor María Marín (Secretaria Ejecutiva) Carmen Isabel Solórzano Ruiz (Tesorera) Edgar Iván Ortiz Lizcano (Presidente Electo) Nilson Roberto de Melo (Pasado Presidente) Comité de Derechos Sexuales y Reproductivos Pío Iván Gómez Sánchez (Coordinador General) José Figueroa (México y Caribe) Ruth Graciela De León (Centroamérica) Rogelio Pérez De Gregorio (Bolivariana) Cristião Fernando Rosas (Cono Sur) Lic. Susana Chávez (Sociedad Civil – Perú) Comité Mortalidad Materna de FLASOG José Douglas Jarquín (Coordinador General) Antonio Peralta Sánchez (México y Caribe) Jesús Octavio Vallecillo (Centroamérica) Pedro Faneite Antique (Bolivariana) Carlos Ortega Soler (Cono Sur) 5 MANUAL FLASOG COAUTORES Nilson Roberto de Melo (Brasil) Francisco Edna Estrada (Colombia) Pío Iván Gómez Sánchez (Colombia) Mike Jimmy Castañeda Castañeda (Colombia) Luis Távara Orozco
    [Show full text]